Short Interest in Alterity Therapeutics Limited (NASDAQ:ATHE) Declines By 36.1%

Alterity Therapeutics Limited (NASDAQ:ATHE) was the target of a large drop in short interest in the month of October. As of October 15th, there was short interest totalling 6,200 shares, a drop of 36.1% from the September 30th total of 9,700 shares. Based on an average trading volume of 14,200 shares, the short-interest ratio is presently 0.4 days. Approximately 0.1% of the company’s shares are short sold.

Alterity Therapeutics Stock Performance

NASDAQ:ATHE opened at $1.15 on Tuesday. The firm’s fifty day simple moving average is $1.30 and its 200 day simple moving average is $1.67. Alterity Therapeutics has a twelve month low of $1.01 and a twelve month high of $5.41.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.